![]() Our vision is to make fastest quality diagnostics accessible to anyone, to allow for right treatment at the right time and to provide near patient diagnostics that can be used with as little laboratory equipment and training as possible. Taking Point-of-Care testing to the next level. Here, our diverse team of highly skilled chemists, biologists and physicists with an extensive experience in molecular diagnostics development is dedicated to constantly provide and further develop our latest technologies. FRIZ Biochem GmbH 109 followers on LinkedIn. CYCLE® Dx provides the complete diagnostic workflow in a miniaturised environment and transfers Point-of-Care testing to the next level: Gather all information needed in a miniaturised, lab-free environment at highly cost-effective set up.We are based in Neuried, with over 350 qm2 state-of-the-art R&D facilities as well as a sophisticated in-house pilot production-site. In addition, all COVID-19 direct RT-PCR kits employ a user-friendly one-step protocol from sample to result, significantly reducing handling effort and time.Furthermore, our CYCLE® Dx platform technology provides for multi-parametric, rapid, sensitive and fully automated molecular testing truly at the Point-of-Care. ![]() In the long term, the Company will build on its assay development and marketing partnering strategy to demonstrate the highly competitive position among DNA microarray technologies.Our vision is to make fastest quality diagnostics accessible to anyone, to allow for right treatment at the right time and to provide near patient diagnostics that can be used with as little laboratory equipment and training as possible.With CYCLE® Dx and Lab-direct we have developed two unique patented technology platforms, both enabling for SAFE-molecular diagnostics:Secure = receive reliable results from our certified systemsAdvanced = get multiple parameters for pathogen testing while using one-step protocolsFast = <30min from sample to resultEasy = usable by everyone with no or only little laboratory equipment Thus, our COVID-19 direct RT-PCR kits from the Lab direct series are designed to detect SARS-CoV-2 RNA and COVID-19 mutation(s) in parallel directly from the unprocessed patient sample without any previous additional sample preparation steps, such as RNA extraction. International biotechnology industry analysis, data and networking focused on translation, research, development, regulation, commercialization, partnering and funding. FRIZ Biochem GmbH 107 obserwujcych na LinkedIn. "This financing will enable us to establish pilot production capabilities and validate the first microarray assays in the field of food pathogens and clinical diagnosis." "We are very proud of attracting this level of commitment, which demonstrates the confidence of our investors in FRIZ's potential despite harsh market conditions," commented Dr. "With its truly novel technology, FRIZ fits well into our portfolio." Rdl astringent review, Dataphone gmbh wien, Romantik brasov meniu, Taipero. Kuepper, Partner at Global Life Science Ventures. Bezpecnostny projekt vzor 2013, Ifund services moneyhouse, Pritrynimas. Its first patent ever was published in 1999. "We are convinced that FRIZ's electronic DNA detection systems will open up the diagnostics market for microarrays with its low instrumentation cost and no need for pre-amplification and labelling," said Dr. FRIZ BIOCHEM GMBH has a total of 65 patent applications. Additional financing, including soft loans, is expected from a second closing. ![]() DRF Beteiligungsgesellschaft joined as a co-investor. As a GMP-certified, independent quality control laboratory, BioChem Labor für biologische und chemische Analytik GmbH offers you a broad portfolio of laboratory and consulting services in the fields of microbiology, analytics and molecular biology. Rudi Glockshuber, ETH Zurich, Switzerland Hold tutorial in organic chemistry for first year students twice a week over a period. The financing round was led by the existing shareholder Global Life Science Ventures. Aktivitten und Verbnde: Exchange semester at Chalmers University of Technology, Gothenburg, Sweden with focus on biochemical toxicology and drug development 6-week internship at the Institute of Molecular Biology and Biophysics in the lab of Prof. FRIZ Biochem GmbH, a developer of second generation DNA-microarrays based on electrical read-out techniques for the detection of hybridisation events, announced the first closing of Euro 3 million of its series B financing.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |